image description

Press Releases

Press Releases

August 2, 2018
Revance Releases Second Quarter 2018 Results

NEWARK, Calif. --(BUSINESS WIRE)--Aug. 2, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018 .

June 14, 2018
Revance to Participate in the JMP Securities Life Sciences Conference 2018

NEWARK, Calif. --(BUSINESS WIRE)--Jun. 14, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference

June 5, 2018
Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

May 29, 2018
Revance to Participate in the Jefferies 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Jefferies 2018 Global Healthcare Conference in New York,
May 29, 2018
Revance Announces Departure of Chief Financial Officer
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance's Chief Financial Officer and Chief Business
May 15, 2018
Revance to Participate in the UBS Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in New
May 9, 2018
Revance Therapeutics Announces Two Recent Additions to Its Management Team
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics , Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher , Ph.D., as Head
Displaying 31 - 40 of 173